NAMSW
NewAmsterdam Pharma Company N.V.
NASDAQ · Healthcare · Biotechnology · NL
$13.88
−3.88%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.50
- Revenue estimate
- $7.5M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.52
- EPS estimate
- -$0.48
- Revenue actual
- $3.7M
- Revenue estimate
- $2.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +61.2%
- Revenue beats (12Q)
- 5
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026